We are live on ! Find out more
NERV icon

Minerva Neurosciences

79 hedge funds and large institutions have $236M invested in Minerva Neurosciences in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 34 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

62% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 21

29% more capital inflows, than outflows

Capital inflows: $13.4M | Capital outflows: $10.5M

0.61% more ownership

Funds ownership: 76.47% → 77.09% (+0.61%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less funds holding

Funds holding: 84 → 79 (-5)

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Holders
79
Holders Change
-5
Holders Change %
-5.95%
% of All Funds
1.7%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
34
Reduced
21
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

NERV Hedge Fund Activity: Q1 2019 in Review

79 of the 4,634 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q1 2019, worth a combined $236M — up 18% from $200M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of NERV and 4 opened new positions — a net loss of 5 holders — while 21 trimmed existing stakes and 34 added.

The largest buyer was GMT Capital, opening a new position worth an estimated $7.49M. The largest seller was Millennium Management, cutting an estimated $2.47M.

  • 79 institutional investors held Minerva Neurosciences (NERV) as of Q1 2019, down from 84 in Q4 2018.
  • Funds reported $236M of Minerva Neurosciences stock for Q1 2019, up 18% quarter-over-quarter.
  • 4 funds opened new Minerva Neurosciences positions in Q1 2019 and 9 closed out, a net change of -5 holders.
  • The largest Minerva Neurosciences buyer in Q1 2019 was GMT Capital, an estimated $7.49M added.
  • The largest Minerva Neurosciences seller in Q1 2019 was Millennium Management, an estimated $2.47M sold.

Based on aggregated 13F filings for Q1 2019.